<DOC>
	<DOCNO>NCT02244879</DOCNO>
	<brief_summary>This research investigate effect resveratrol inflammatory mediator type 2 diabetic patient vivo . The investigator also investigate hypothesis resveratrol antioxidant activity , improve insulin sensitivity lipid pattern , down-regulates bone-turnover .</brief_summary>
	<brief_title>Effects Resveratrol Inflammation Type 2 Diabetic Patients</brief_title>
	<detailed_description>Despite large body evidence demonstrate promising effect resveratrol rodent , human study still lack preventive therapeutic value resveratrol human remain elucidated . The published evidence sufficiently strong recommend administration resveratrol human , beyond dietary source . On hand , animal data promise prevention various cancer type , coronary heart diseases diabetes strongly indicate need human clinical trial . Furthermore , data lack either safety long-term administration , efficacy resveratrol administration patient chronic illness , diabetes mellitus . The main objective study investigate effect resveratrol inflammatory mediator type 2 diabetic patient vivo . This research investigate hypothesis resveratrol , give orally type 2 diabetic subject 24 week induce decrease value high-sensitivity CRP ( C-reactive protein ) ( primary outcome measure ) , IL-6 ( Interleukin-6 ) , PTX3 ( pentraxin 3 ) . The investigator also investigate hypothesis resveratrol antioxidant activity , improve insulin sensitivity lipid pattern , down-regulates bone-turnover . Secondary outcome therefore variation follow variable : TAS ( total antioxidant status ) , glycemia , glycated hemoglobin ( HbA1c ) , Homeostasis model assessment insulin resistance ( HOMA-IR ) , total HDL-cholesterol , triglyceride , adiponectin , body composition ( evaluate Dual-emission X-ray absorptiometry DXA- ) , bone mineral density ( DXA ) . Finally , investigator interest evaluate efficacy , safety tolerability two different dosage resveratrol : 500 mg/day 40 mg/day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>1 . 35 year age old 2 . Type 2 diabetes body mass index ( BMI ) &lt; 35 kg/m2 3 . Subjects hypoglycemic agent insulin 4 . Willing give write informed consent able understand , participate comply study requirement . 1 . Subjects antioxidant medication 2 . Patient nonsteroidal antiinflammatory drug , steroid insulin 3 . On agent significant antioxidant property 4 . History drug alcohol abuse 5 . Liver kidney diseases 6 . Any life threatening diseases 7 . Allergy peanut , grape , wine , mulberry 8 . Pregnant woman 9 . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass surgery coronary angioplasty ) previous four Weeks 10 . Subjects anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>resveratrol</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>inflammation</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>body composition</keyword>
	<keyword>bone mass</keyword>
</DOC>